Jubilant Pharmova Limited announced the completion of a United States Food and Drug Administration (USFDA) inspection at its Jubilant HollisterStier LLC (JHS) contract manufacturing facility in Spokane, Washington. The inspection, which took place on June 17, 2026, resulted in eight observations, none of which were related to sterility assurance concerns. JHS will submit its response within 15 business days, reinforcing the company’s commitment to addressing all findings.
USFDA Inspection Completed at Spokane Facility
Jubilant Pharmova Limited has announced the conclusion of an inspection by the United States Food and Drug Administration (USFDA) at its subsidiary, Jubilant HollisterStier LLC (JHS), contract manufacturing facility located in Spokane, Washington, U.S.A. The inspection occurred on June 17, 2026.
Inspection Outcome
The USFDA issued a total of eight observations following the inspection. Importantly, none of these observations are related to sterility assurance concerns, indicating the facility’s adherence to critical quality standards in this area. Jubilant HollisterStier LLC will be responding to these observations within 15 business days, demonstrating the company’s commitment to a comprehensive and timely resolution of all identified points.
About Jubilant HollisterStier LLC
Jubilant HollisterStier LLC is recognized as a leading integrated contract manufacturer specializing in sterile injectables, including lyophilized products, as well as ophthalmic solutions. The company provides specialized manufacturing services tailored for the pharmaceutical and biopharmaceutical industries, offering a full spectrum of support from process qualification through commercial release.
Source: BSE
